Longevity network
Longevity Centers of America (Netzwerk)
- Hormone therapy (HRT / BHRT)
- Peptide therapy
ListedView profile →
§ — Substance profile
A
Tesamorelin
Egrifta · Growth-hormone-releasing hormone analogue
01 — Regulatory status
Regulatory status · United States · as of September 2026
FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Use for any other purpose is off-label.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
- Approved drug with randomized controlled trials for the approved indication
- Human clinical data exists, but no approval for the researched use
- Animal or in-vitro data only, no controlled human trials
- No published clinical data; use rests on anecdote
A
B
C
D
Reviewed September 2026 · Sources: FDA, EMA
02 — Researched for
What is being studied.
Visceral fat reduction in HIV lipodystrophy; NAFLD; cognitive function in older adults.
03 — What the evidence shows
The published record.
Phase 3 trials showed roughly 15–18% visceral fat reduction in the approved population. A NIH-funded trial found modest cognitive effects in older adults; not replicated at scale.
04 — What is claimed but not shown
Claimed, not demonstrated.
Visceral fat loss in healthy adults without lipodystrophy; general anti-aging benefit.
05 — Known risks
Documented risks.
Glucose intolerance, fluid retention, arthralgia; contraindicated in active malignancy; effect reverses on discontinuation.
06 — Researched for these goals
Where Tesamorelin appears.
07 — Questions for your physician
Six questions worth printing.
- 01What is your primary board certification, and in what year did you obtain it?
- 02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
- 03Which human trials support this use, and what were their size and duration?
- 04Where does the product come from, and can you show me a certificate of analysis for this batch?
- 05What outcome will we measure, when, and what happens if it does not improve?
- 06What is the total cost for the first three months, in writing?
Providers offering peptide therapy
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.